ERBB2 and breast cancer: Our experiments demonstrated that the treatment with PSE and PHY was most effective in MCF-7 cells representing the luminal (ER+/PR+) breast cancer subtype, while the lowest sensitivity was observed in HER2-positive SK-BR-3 cells.